


fast-track


DIAGNOSTICS

TRUE POSITIVES. TRUE NEGATIVES.

Syndromic real-time PCR multiplexing kits



Reliable



Lyophilised

Sensitive

Respiratory infections kits

Respiratory infections are responsible for a significant morbidity worldwide and are a leading cause of death in children in developing countries. Infectious agents can be viruses, bacteria and fungi but as these different pathogens show the same range of symptoms, it is impossible to identify the causative agent just by the clinical picture. A proper diagnosis is needed to differentiate between those pathogens, to detect co-infections and to prevent overuse of antibiotics that has already led to increasing drug resistance.

Features of the kits

The largest range of real-time PCR kits available for the rapid detection of respiratory infections

- > **Lyophilised:** all the reagents required included in a single patient sample tube, you just need to add nucleic acid extract.
- > **Quality:** CE-IVD (*in vitro* diagnostic), external quality assessments and external/internal clinical performance evaluations.
- > **Accuracy:** high sensitivity, high specificity - more than 97.4% of true positives and true negatives.
- > **Reliability:** consistent results with excellent repeatability and reproducibility.
- > **Fast:** one-step syndromic real-time PCR multiplexing kits detecting simultaneously viruses, bacteria or fungi.
- > **Flexibility:** all FTD and FTlyo kits have the same pipetting and PCR protocol and can be performed in the same run.
- > **Compatibility:** can be used with most extraction and PCR platforms on the market.
- > **Robustness:** tested for stability up to 24 months with no significant differences noted.
- > **Shelf life:** 12 months from manufacture.
- > **Packaging:** flexible 32 or 64 reaction size.
- > **Cost-effective:** competitive prices, value for money offer.

Quality assured

All FTD kits are regularly controlled by Quality Control for Molecular Diagnostics (QCMD) panels and other external quality assessment programs. In addition, FTD kits undergo pre- and post-market clinical performance evaluation studies. See example below:

	QCMD		Instand e.V.		Clinical samples	
	Samples confirmed	Overall agreement	Samples confirmed	Overall agreement	Samples confirmed	Overall agreement
FTD Respiratory pathogens 33	611/635*	96.22%	268/268	100%	1124/1128*	99.65%
FTD FLU/HRSV	76/76	100%	60/60	100%	236/236	100%

*Discrepant results were obtained from low positives or educational samples

For complete quality data, please refer to the product manuals and validation files available on FTD's website.

Some examples of FTD Respiratory infections kits

Visit FTD's website to access the full list.

	Respiratory pathogens 16	Respiratory pathogens 21	Respiratory pathogens 21 plus	Respiratory pathogens 33	FLU	FLU/HRSV	Flu differentiation
<i>Bordetella</i>				>			
<i>Chlamydia pneumoniae</i>			>	>			
enterovirus		>	>	>			
<i>Haemophilus influenzae</i>				>			
<i>Haemophilus influenzae B</i>			>	>			
human adenovirus	>	>	>	>			
human bocavirus		>	>	>			
human coronavirus 229E	>	>	>	>			
human coronavirus HKU1	>	>	>	>			
human coronavirus NL63	>	>	>	>			
human coronavirus OC43	>	>	>	>			
human metapneumoviruses A/B	>	>	>	>			
human parainfluenza virus 1	>	>	>	>			
human parainfluenza virus 2	>	>	>	>			
human parainfluenza virus 3	>	>	>	>			
human parainfluenza virus 4	>	>	>	>			
human parechovirus		>	>	>			
human respiratory syncytial viruses A/B	>	>	>	>		>	
human rhinovirus	>	>	>	>			
influenza A virus	>	>	>	>	>	>	
influenza A(H1N1)swl virus		>	>	>	>		>
influenza A(H3) virus							>
influenza A(H5) virus							>
influenza A(H7) virus							>
influenza B virus	>	>	>	>	>	>	
influenza C virus				>			
<i>Klebsiella pneumoniae</i>				>			
<i>Legionella pneumophila/longbeachae</i>				>			
<i>Moraxella catarrhalis</i>				>			
<i>Mycoplasma pneumoniae</i>		>	>	>			
<i>Pneumocystis jirovecii</i>				>			
<i>Salmonella</i>				>			
<i>Staphylococcus aureus</i>			>	>			
<i>Streptococcus pneumoniae</i>			>	>			

Quotes from publications

“Routine multiplex PCR analysis fosters the detection of respiratory viruses in children with febrile seizure... By defining those children with an underlying viral illness, multiplex PCR analysis has the potential to facilitate cohortation of these patients and to reduce unnecessary use of antibiotics in the future.”

Naric, J., J. Rissland, A. Simon, M. Poryo, L. Gortner and S. Meyer (2016). “Role of multiplex PCR analysis in children with febrile seizures.” Wiener Medizinische Wochenschrift: 1-5. .

“Multiplex, syndromic testing can overcome underdiagnosing of important respiratory pathogens thus, allowing improved, targeted therapy or application of appropriate infection control measures.”

Dalpe, A., S. Zimmermann and P. Schnitzler (2016). “Underdiagnosing of Mycoplasma pneumoniae infections as revealed by use of a respiratory multiplex PCR panel.” Diagnostic Microbiology and Infectious Disease 86(1): 50-52.

Fast Track Diagnostics Ltd., Seaview, No. 2, Qui-Si-Sana Seafront, Sliema, SLM 3110, Malta
Sales enquiries: T +356 2765 4302 • F +356 2765 4303 • E order@fast-trackdiagnostics.com

Technical enquiries: T +352 281 098-1 • E support@fast-trackdiagnostics.com

Administrative and finance enquiries: T +356 2765 4302 • F +356 2765 4303 • E info@fast-trackdiagnostics.com

Legal Manufacturer - Fast Track Diagnostics Luxembourg S.à.r.l.: 29, rue Henri Koch, L-4354 Esch-sur-Alzette

FTD.MK8.EN.2017.2

www.fast-trackdiagnostics.com